ATE393780T1 - Reinigungsverfahren zur grossmassstabigen produktion von gc-globulin, damit erhaltenes produkt und dessen verwendung in medizin - Google Patents

Reinigungsverfahren zur grossmassstabigen produktion von gc-globulin, damit erhaltenes produkt und dessen verwendung in medizin

Info

Publication number
ATE393780T1
ATE393780T1 AT02754557T AT02754557T ATE393780T1 AT E393780 T1 ATE393780 T1 AT E393780T1 AT 02754557 T AT02754557 T AT 02754557T AT 02754557 T AT02754557 T AT 02754557T AT E393780 T1 ATE393780 T1 AT E393780T1
Authority
AT
Austria
Prior art keywords
globulin
medicine
scale production
purification process
product
Prior art date
Application number
AT02754557T
Other languages
English (en)
Inventor
Charlotte Svaerke Jorgensen
Inga Laursen
Gunnar Houen
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Application granted granted Critical
Publication of ATE393780T1 publication Critical patent/ATE393780T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
AT02754557T 2001-08-14 2002-08-12 Reinigungsverfahren zur grossmassstabigen produktion von gc-globulin, damit erhaltenes produkt und dessen verwendung in medizin ATE393780T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200101217 2001-08-14

Publications (1)

Publication Number Publication Date
ATE393780T1 true ATE393780T1 (de) 2008-05-15

Family

ID=8160667

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02754557T ATE393780T1 (de) 2001-08-14 2002-08-12 Reinigungsverfahren zur grossmassstabigen produktion von gc-globulin, damit erhaltenes produkt und dessen verwendung in medizin

Country Status (9)

Country Link
EP (1) EP1419177B1 (de)
JP (1) JP2005508892A (de)
AT (1) ATE393780T1 (de)
AU (1) AU2002321012B2 (de)
CA (1) CA2456843A1 (de)
DE (1) DE60226327T2 (de)
DK (1) DK1419177T3 (de)
ES (1) ES2305272T3 (de)
WO (1) WO2003016348A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101005859B (zh) * 2004-06-29 2012-08-15 利莱恩斯生命科学有限公司 灭病毒生物液体的制备方法
CN100354301C (zh) * 2005-10-13 2007-12-12 南京工业大学 化学合成多肽的新型大规模分离制备技术
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
CN103038247A (zh) * 2010-05-18 2013-04-10 Abbvie公司 蛋白质提纯的装置和方法
EP2612921B1 (de) 2010-09-03 2016-11-02 Morita Pharmaceutical Ind., Ltd. Verfahren zur herstellung von neuem degalactosyliertem gc-globulin
EP2682168A1 (de) 2012-07-02 2014-01-08 Millipore Corporation Reinigung biologischer Moleküle
LT3081221T (lt) 2013-12-13 2021-09-10 Saisei Pharma Co., Ltd. Farmacinė kompozicija, apimanti fermentu apdorotą galvijo priešpienį
DK3131589T3 (da) * 2014-04-15 2023-08-07 Boehringer Ingelheim Int Fremgangsmåde og anvendelse til fortløbende inaktivering af en virus under tilvejebringelse af et biologisk produkt
ES2942850T3 (es) * 2015-06-01 2023-06-07 Saisei Pharma Co Ltd Producto lácteo tratado con enzimas, procedimiento para producirlo, composición y producto

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177002A (en) * 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor
ES2124702T3 (es) * 1990-04-11 1999-02-16 Brigham & Womens Hospital Usos terapeuticos de compuestos que se unen a actina.
US6268478B1 (en) * 1996-02-12 2001-07-31 Cedars-Sinai Medical Center Intracellular vitamin D binding protein

Also Published As

Publication number Publication date
DE60226327T2 (de) 2009-07-09
DE60226327D1 (de) 2008-06-12
EP1419177A2 (de) 2004-05-19
EP1419177B1 (de) 2008-04-30
CA2456843A1 (en) 2003-02-27
ES2305272T3 (es) 2008-11-01
WO2003016348A2 (en) 2003-02-27
JP2005508892A (ja) 2005-04-07
DK1419177T3 (da) 2008-08-25
WO2003016348A3 (en) 2004-03-04
AU2002321012B2 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
DK1692516T3 (da) Terapifremgangsmåde
US10005823B2 (en) Peptides having effects on promoting wound healing, collagen production, angiogenesis, activation of immunocytes and applications thereof
EP1728076A4 (de) System und verfahren zur bereitstellungoptimaler konzentrationen für medikamentinfusionen
WO1995025171A3 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
ATE393780T1 (de) Reinigungsverfahren zur grossmassstabigen produktion von gc-globulin, damit erhaltenes produkt und dessen verwendung in medizin
RU95110699A (ru) Устройство для обработки крови, озоновый генератор для производства озона, устройство для контакта газа и жидкости, способ инактивации вируса иммунодефицита человека в белковом материале
WO2006102933A8 (en) Preparation of autologous haematopoietic stem cells, the methods of production, cyropreservation and use for therapy of traumatic diseases of the central nervous system
ATE121424T1 (de) Hpth-fragment-(1-37), seine herstellung, dieses enthaltende arzneimittel und seine verwendung.
YU73301A (sh) eNOS MUTACIJE,NJIHOVA UPOTREBA ZA PRIPREMU LEKA ZA GENSKU TERAPIJU I POSTUPCI TERAPEUTSKOG SKRININGA
DE3914869C1 (de)
JPS6279790A (ja) 改質されたヒアルロン酸の製造法
GR3024457T3 (en) Method and composition for determining the immunological activity of bioactive substances.
Olaniyan et al. Raw Cucumber (Cucumis sativus) Fruit Juice as Possible First-Aid Antidote in Drug-Induced Toxicity
Zhang et al. Electroacupuncture promotes nerve regeneration and functional recovery in rats with spinal cord contusion through the coordinate interaction of CD4 and BDNF
JPS6041615A (ja) コロニ−形成刺激因子の製造方法
EP2511288B1 (de) Verfahren zum Erhalten von Inhibitoren von Cystein-Peptidasen mit einer elektrophoretischen Reinheit aus biologischen Materialien
WO2001064240A3 (en) Methods for promoting production of myelin by schwann cells
CN107183478A (zh) 一种葡萄汁处理装置
Jeon et al. Investigating effects of negative emotional states on the korean elderly's osteoarthritis prevalence
Ravliv et al. Investigation of the Amino Acid Composition of Tablets on the basis of Cryolophilized Xenoderm of Pigs
RU2489172C1 (ru) Способ проведения лечебного дискретного плазмафереза с экстракарпоральной модификацией эритроцитов и лейкоцитов индукторами интерферона, антиоксидантами и протекторами клеток
Steinbuch IX. Notes on the Production of Plasma Derivatives in France
PH22020050168Y1 (en) Process for isolating and producing antibodies for the prevention and treatment of covid-19 and related diseases from blood plasma containing said antibodies
PH22020050169U1 (en) Intravenous pharmaceutical form of isolated and purified antibodies for the prevention and treatment of covid-19 and related diseases
Isbister et al. Estimation of brown snake antivenom dose in envenomed patients and with in vitro studies

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties